Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” ...

New advancements in Cold Agglutinin Disease treatments promise improved patient outcomes and market growth, driving innovation and investment in the sector.

Shares of the company rose about 1% at $185.20 in premarket trading. The drugmaker has slashed jobs and pulled the plug on ...

Resources are abundant. With access to vast financial resources, U.S. companies can make bold moves. They don’t just wait for ...

US equity futures were in holding mode as traders waited for the third-quarter earnings season to move into top gear, with the first of the “Magnificent Seven” big-tech giants — Google parent Alphabet ...

Novartis CEO Vas Narasimhan discusses the company's quarterly earnings as the drugmaker lifted profit guidance for a third ...

The previous update I wrote on Novartis was the Q2 earnings preview and I want to note that while my estimates on some of the key growth products were off, the general direction of my prediction ...

She goes on to share the following market-specific initiatives: In South Korea, Novartis Korea partnered with the Seoul Metropolitan Government, and the Korean Society of Interventional Cardiology are ...

North Korea has said it had found the remnants of a South Korean military drone and that any further "violation" of its territory would result in a "declaration of war." Tensions between the two ...

SEOUL: North Korea said on Saturday (Oct 19) it had discovered the remains of a crashed South Korean military drone, suggesting it was on a propaganda mission in the latest confrontation between ...